In breast cancer, the most common CR-APA is intronic polyadenylation (IPA) where the PAS is located in an intron (Table 1). It has been shown that IPA events occur in about 20% of human genes, mostly generating mRNAs of different isoforms encoding different protein products (Tian et al., 2007). Elkon et al. (2012) detected MCF-10A cells in different physiological states by deep sequencing and found that cells in the proliferative state had enhanced cleavage and polyadenylation of intron PAS compared to MCF-10A in the arresting state. Further IPA events of RNF220 and FAM700B genes were detected in cells in the proliferative state by 3′-end RT-PCR analysis (Elkon et al., 2012). IPA is not only seen in normal breast epithelial cells in a proliferative state but also in different types of breast cancer cells or tissues. For example, the ELP5, ERO1A, and PHFT1 genes in MCF7 cells can generate truncated mRNA transcripts through IPA, producing truncated proteins with aberrant functions or dominant negative effects (Turner et al., 2020); PRMT2 Pre-mRNA in breast cancer tissues generates the shorter transcript PRMT2L2 via IPA, which is associated with ERα-positive status and may be involved in breast cancer formation and progression by regulating the estrogen-ERα signaling pathway (Zhong et al., 2011). Confocal microscopy findings showed different intracellular localization of wild-type PRMT2 and PRMT2L2, suggesting that the truncated proteins produced by IPA may alter the cellular localization of the original proteins. In addition, the truncated proteins produced by IPA may also be involved in breast cancer development and progression by inhibiting the function of full-length proteins. In MDA-MB-231 cells, the truncated MAGI3 protein produced by IPA was unable to bind to the oncoprotein YAP compared to the intact MAGI3 protein, and YAP was released, further activating downstream signaling pathways and accelerating the malignant transformation of human breast epithelial cells (Ni and Kuperwasser, 2016).

UTR-APA is associated with tissue type and cellular status, and its mediated 3′UTR shortening is commonly found in highly proliferative, poorly differentiated cancer cells (Pereira-Castro and Moreira, 2021). 3′UTR shortening has been reported to be widespread in different types of breast cancer (Table 1). Xia et al. (2014) analysed RNA-seq data from seven tumour types, including breast cancer, by DaPars, and identified a large number of highly specific genes associated with tumours, more than 90% of which underwent UTR-APA-mediated 3′UTR shortening. Wang et al. (2015) analysed APA sites in luminal B breast cancer (ER + PR + Her2^+/−) by sequencing APA sites (SAPAS) method and bioinformatics, and also found a large number of 3′UTR-shortening genes, which are closely related to the spliceosome and Wnt receptor signaling pathway. A large number of 3′UTR-shortening genes have also been found in triple-negative breast cancer (TNBC) tissues, and most of them are associated with tumour cell proliferation and clinical prognosis of patients (Akman et al., 2015; Wang et al., 2019). In addition to the global effect of UTR-APA dysregulation on breast cancer-related genes, it can also affect the proliferation, migration and invasion of breast cancer by regulating the APA patterns of individual oncogenes or tumour suppressor genes. Mayr and Bartel found that the oncogene IGF2BP1/IMP-1 undergoes more 3′UTR shortening in breast cancer tissues compared to paraneoplastic tissues. If the shorter IGF2BP1/IMP-1 mRNA isoforms were transiently transfected into normal breast cell lines, the normal breast cells would undergo malignant transformation and have a significantly higher proliferative capacity (Mayr and Bartel, 2009). PPRELID1 is a gene that promotes tumour cell growth. Gillen et al. (2017) sequenced polyadenylation sites (PAS-seq) and found that the 3′UTR of PRELID1 gene mRNA in ER-positive breast cancer cells was significantly shortened, and its stability and translational efficiency were significantly increased, which in turn increased the growth capacity of tumour cells (Gillen et al., 2017). Ki67, which is closely related to cancer cell proliferation, can also increase its protein expression through 3′UTR shortening, thus enhancing the proliferation ability of breast cancer (Yan et al., 2018). Guo et al. (2022) identified a novel p62 mRNA isoform with a short 3′UTR (p62-SU) associated with breast cancer chemoresistance by RNA sequencing (RNA-seq). Overexpression of P62-SU enhanced the proliferation, migration, invasion and chemoresistance of breast cancer cells compared to the p62 mRNA isoform with full-length 3′UTR (p62-LU) (Guo et al., 2022). In addition, HuR in ER + breast cancer cells (Tan et al., 2017), NRAS and c-JUN in TNBC tissues (Miles et al., 2016) and AGR2 in human breast cancer tissues (Matoulkova et al., 2017) are oncogenes that can evade miRNA-mediated repression through 3′UTR shortening, increase their mRNA stability and translational efficiency, and contribute to the development of breast cancer. Notably, some proliferative signals (e.g., epidermal growth factor and estrogen) can induce further shortening of the 3′UTR of oncogenes (Akman et al., 2012; Akman et al., 2015). The shortening of the 3′UTR caused by UTR-APA not only directly activates proto-oncogenes, but also indirectly downregulates the expression of tumour suppressor genes. This is because UTR-APA produces 3′UTR shortening genes that compete with tumor suppressor genes to form endogenous RNA (ceRNA). Therefore, the originally bound miRNA is released and redirected to tumor suppressor genes with the same miRNA target site, thereby reducing the expression of tumor suppressor genes, such as PHF6 and LARP1 (Park et al., 2018). In addition, 3′UTR shortening can regulate the stability of mRNAs of proto-oncogenes and tumor suppressor genes through RBP and affect their protein expression, thus exerting a pro-carcinogenic effect (Masamha and Wagner, 2018).

In conclusion, CR-APA and UTR-APA are closely related to breast cancer. CR-APA plays a relatively limited role, mainly by changing the protein structure, affecting the function of oncoprotein and tumor suppressor protein, and promoting tumor progression. UTR-APA, which is more widely distributed, participates in the occurrence and development of breast cancer by directly activating proto oncogenes, indirectly inhibiting tumor suppressor genes by interfering with ceRNA networks, and mediating RBP to affect the stability of key genes. It is worth noting that not all genes are regulated by APA, and not all APA mediated 3′UTR shortening can increase protein expression levels. Only when miRNA or RBP targeting the 3′UTR gene is significantly expressed, its stability and expression level will be affected (Masamha and Wagner, 2018).

CFIm25 (also known as CPSF5, or NUDT21) and CFIm68 (also known as CPSF6) are both subunits of the CFIm complex. It has been demonstrated that both CFIm25 and CFIm68 are key regulators of APA, involved in PAS selection and regulation of 3′ UTR length (Jafari Najaf Abadi et al., 2019; Kurozumi and Lupold, 2021). Knockdown of both regulators promotes preferential selection of the proximal PAS, resulting in an overall shortening of the 3ʹUTR of the transcript, which increases the stability and expression level of the target gene. In addition, CFIm25 influences the selection of PAS by chromatin-regulated genes and is involved in cell fate reprogramming (Brumbaugh et al., 2018). Although CFIm25 and CFIm68 act in concert in PAS selection, their roles are completely opposite in breast cancer. IHC analysis shows that CFIm25 is under-expressed in breast cancer tissues compared to tissues with benign breast disease. Overexpression of CFIm25 inhibits cancer cell proliferation, migration, invasion and Epithelial-mesenchymal transition (EMT) (Wang et al., 2020a). In addition, CFIm25 itself can be regulated by miRNAs as a target gene, suggesting that regulating the expression level of CFIm25 by miRNAs is expected to improve cancer treatment (Tamaddon et al., 2020). CFIm68, on the other hand, is involved in breast cancer progression as an oncogenic factor (Binothman et al., 2017). Binothman et al. (2017) found that high expression of CFIm68 in BC was associated with poor patient prognosis. Knockdown of CFIm68 significantly reduced cell viability, inhibited colony forming ability and induced apoptosis in invasive breast cancer cells. The specific molecular mechanism is that CFIm68 promotes tumourigenesis by enhancing the A-to-I RNA editing process, an RNA processing mechanism that is one of the major factors driving tumourigenesis (Binothman et al., 2017). Interestingly, CFIm25 was able to negatively regulate CFIm68, and knockdown of CFIm68 reversed cancer cell migration and invasion induced by low CFIm25 expression, but the mechanism by which CFIm25 and CFIm68 interacted has not been clarified (Wang et al., 2020a).

The poly (A) polymerase (PAP) family is a core member of the polyadenylation mechanism, and PAP is mainly responsible for the addition of the poly (A) tail of mRNA (Mohanan et al., 2022). It is known that there are three subtypes of typical PAPs, encoded by different genes, namely, PAPOLA, PAPOLB, and PAPOLG. Through RNA sequencing and bioinformatics analysis, Li et al. (2017) found that the 3ʹUTR of the gene was prolonged after PAPOLA silencing, indicating that PAPOLA has the ability to promote proximal PAS selection. PAPOLA is generally overexpressed in breast cancer, and overexpression of PAPOLA can shorten the 3ʹUTR of cyclin D1 (CCND1) mRNA, increase the protein expression of CCND1, and then promote the proliferation of breast cancer cells (Komini et al., 2021).

PABPN1 is a key factor involved in APA formation, which not only increases the ability of PAP to sustain tail addition, but also controls the length of the poly(A) tail (Kurozumi and Lupold, 2021). PABPN1 was identified as a potent repressor of proximal PAS selection, and its reduced expression leads to an overall shortening of the 3′UTR (Xiang et al., 2018). PABPN1 has been reported to be associated with human cancer progression. PABPN1 is lowly expressed in non-small cell lung and bladder cancers and functions as a tumor suppressor (Ichinose et al., 2014; Chen et al., 2023). However, in TNBC, PABPN1 is highly expressed, and knockdown of PABPN1 inhibits cell proliferation, promotes apoptosis, leads to cell cycle redistribution, and reverses APA events in genes associated with tumourigenesis, proliferation, metastasis, and chemo-sensitivity in breast cancer (Wang et al., 2020b).

Heterogeneous nuclear ribonucleoprotein C (hnRNPC) is an RNA-binding protein involved in the regulation of APA (Dharmalingam et al., 2022). Gruber et al. (2016) sequenced the 3ʹ end of the pre-mRNA after knockdown of hnRNPC and found that knockdown of hnRNPC increased the use of intronic PAS and an increase in the occurrence of IPA, which resulted in the production of truncated proteins or the effective downregulation of functional full-length transcripts production. Knockdown of hnRNPC also increases the use of distal U-rich PAS in the 3′UTR, leading to overall lengthening of the 3ʹUTR of target genes (Mo et al., 2022). It is suggested that aberrant expression of hnRNPC can dysregulate the IPA and UTR-APA processes of target genes, which are involved in tumour development. MTHFD1L is a key enzyme in mitochondrial folate metabolism, which is closely related to cell proliferation (Fischl et al., 2019). In metastatic colonic epithelial cells, overexpression of hnRNPC can both upregulate the content of functional full-length transcript isoforms of MTHFD1L through IPA, and shorten the 3ʹUTR of MTHFD1L to improve translational efficiency, which together increase the protein expression level of the full-length MTHFD1L and play an oncogenic role. In breast cancer, high expression of hnRNPC inhibits the interferon response and promotes breast cancer cell proliferation by down-regulating dsRNAs, and high hnRNPC expression is associated with advanced clinical stage and shorter survival time (Wu et al., 2018; Lv et al., 2021). These regulated dsRNAs are mainly derived from pre-mRNA introns carrying hnRNPC binding sites, suggesting that the oncogenic role of hnRNPC in breast cancer may be associated with increased IPA occurrence (Wu et al., 2018).

U1 snRNP is involved in splice site recognition and protects nascent RNAs from premature cleavage and polyadenylation (PCPA) through a mechanism known as “Telescripting” thus ensuring transcriptome integrity and participating in the regulation of mRNA length (Kaida et al., 2010; Berg et al., 2012; Kurozumi and Lupold, 2021). When U1 snRNP is inhibited, many cryptic polyadenylation signals (PASs) located on the pre-mRNA intron or at other locations are activated, leading to PCPA. Therefore, inhibition of U1 snRNP enhances the usage of proximal PASs, leading to an overall shortening of transcripts. Lu et al. (2023) found that the subunit of U1 snRNP, SNRPC, is beneficial for the RNAP II-controlled transcriptional process. In triple-negative breast cancer, SNRPC enhances cancer cell invasiveness by accelerating RNAP II-controlled oncogene transcription (Lu et al., 2023).

Cytoplasmic polyadenylation element binding protein 1 (CPEB1) can both control poly(A) tail length to regulate mRNA translation and influence the overall 3′UTR length (Bava et al., 2013). CPEB1 mediates the shortening of the mRNA 3′UTR in the nucleus, mainly by promoting the use of proximal PAS by CPSF (Pereira-Castro and Moreira, 2021). Nagaoka et al. (2016) found that CPEB1 was lowly expressed in highly metastatic breast cancer cells, whereas the metastasis-promoting factor matrix metalloproteinase 9 (MMP9) was highly expressed. Experimental analyses revealed that CPEB1 deletion leads to lengthening of the poly (A) tail of MMP9 mRNA and enhances translation efficiency (Nagaoka et al., 2016). In addition, CPEB1 is regulated by estrogen, which promotes the proliferation and migration of breast cancer cells by down-regulating CPEB1 expression (Sovijit et al., 2021).

Many APA regulators are abnormally expressed in breast cancer. They are involved in breast cancer development by regulating the selection of oncogenes and tumor suppressor genes PAS, affecting their mRNA stability and translation efficiency. Among them, CFIm25, CFIm68, and PABPN1 promote the selection of distal PAS, and their overexpression can lead to global shortening of 3′UTR. CPSF1, CSTF2, CSTF3, hnRNPC, PCF11, CPEB1, RBBP6, and PAPOLA promote the use of proximal PAS, and their overexpression can lead to global elongation of 3′UTR (Table 2).